Showing results (1451-1460 of 6,957) with videos related to
Sort By:
Pageof 696
Journal of Clinical Pharmacology|June 25, 2016
Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of LemborexantPatricia J Murphy, Sanae Yasuda, Kenya Nakai, et al.Journal of Clinical Pharmacology|June 14, 2016
AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected SepsisShankar Lanke, Tian Yu, Joseph E Rower, et al.Journal of Clinical Pharmacology|December 1, 1989
Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humansM R Weir, D K Klassen, N Hoover, et al.Journal of Clinical Pharmacology|December 1, 1989
Comparison of oral and aerosol ribavirin regimens in the high risk elderlyJ M Bernstein, H Liss, S D ErkJournal of Clinical Pharmacology|February 27, 2016
The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma PatientsCynthia M Nijenhuis, Alwin D R Huitema, Serena Marchetti, et al.Journal of Clinical Pharmacology|March 19, 2016
Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 InhibitorJack G Shi, Xuejun Chen, Naresh G Punwani, et al.Journal of Clinical Pharmacology|December 4, 2015
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal CancerMichelle A Rudek, Arvind Dasari, Daniel Laheru, et al.Journal of Clinical Pharmacology|December 4, 2015
Guaifenesin Pharmacokinetics Following Single-Dose Oral Administration in Children Aged 2 to 17 YearsGary A Thompson, Gail Solomon, Helmut H Albrecht, et al.Journal of Clinical Pharmacology|August 5, 2015
Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010Gary R Matzke, Thomas C Dowling, Samantha A Marks, et al.Journal of Clinical Pharmacology|December 24, 2014
Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrationsSandra Bodeau, Eric Nguyen-Khac, Caroline Solas, et al.Pageof 696